Researchers evaluated combination therapy with MEK inhibitor selumetinib and MDM2 inhibitor KRT-232 in TP53 wild-type and mitogen-activated protein kinase (MAPK) altered colon and thyroid cancer models.
[Scientific Reports]
Sorry, but the selected Zotpress account can't be found.